



<b>What is the Drug Wastage Program?</b>	<ul style="list-style-type: none"><li>• Effective January 1, 2024, the Drug Wastage Program is an expansion of the voluntary program managed by Magellan Rx for Blue Cross.</li><li>• This program identifies specific authorizations for a targeted list of drugs. It requires rounding the dosage down (within 10% of the requested dose) to allow for more efficient vial-size utilization when clinically appropriate. This program is designed to reduce waste, improve the efficiency of healthcare, and provide high-quality patient care.</li><li>• The practice of rounding doses when they are within this 10% threshold is supported by the Hematology/Oncology Pharmacy Association (HOPA), National Comprehensive Cancer Network (NCCN), and the American Society of Clinical Oncology (ASCO).</li><li>• A reduction in dose within 10% of the requested dose should not result in a clinically meaningful difference in the efficacy of the therapeutic product.</li></ul>
<b>Who is Magellan Rx?</b>	Magellan Rx is an independent company that specializes in managing provider-administered drugs covered under the medical benefit. Magellan Rx has served as our Medical Drug Benefit Manager since 2019 and oversees our existing Provider-Administered Drug Review (PAD) program for non-oncology drugs. They began managing oncology drugs effective January 1, 2024.
<b>How will my patients be impacted by the Drug Wastage Program on January 1, 2024?</b>	No patient impact is anticipated.
<b>How will providers be impacted by the Drug Wastage Program?</b>	<ul style="list-style-type: none"><li>• Magellan Rx will contact providers after they submit a precertification request for drugs included in this program if the particular case would require a dose rounding adjustment.</li><li>• Dose rounding ultimately eases the compounding process for pharmacy personnel.</li><li>• Providers can appeal the determination to round the dose down to the nearest vial size when within 10% of the requested dose if the patient medically requires the higher dose. Appeals can be made to Magellan Rx at 1-800-424-8270.</li><li>• If a dose or frequency changes during the course of therapy, providers should contact Magellan Rx at 1-800-424-8270 to update the authorization in order to receive appropriate reimbursement.</li></ul>
<b>How were providers notified of this program?</b>	This announcement was posted on Provider News and sent via Provider Notify in September 2023.